Related Experiment Video
Updated: Aug 2, 2026

Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease
Published on: February 9, 2016
Aflatoxin M1 absorption and cytotoxicity on human intestinal in vitro model
F Caloni1, A Stammati, G Friggè
1Department of Veterinary Sciences and Technologies for Food Safety, University of Milan, via Celoria 10, 20133 Milan, Italy. francesca.caloni@unimi.it
Abstract:
Aflatoxin M1 (AFM1) is the principal hydroxylated Aflatoxin B1 (AFB1) metabolite and is detected in milk of mammals, after consumption of feed contaminated with AFB1. As it is classified as probable human carcinogen (group 2B of the IARC), most countries have regulated its maximum allowed levels in milk in order to reduce AFM1 risk (50 ng/kg the EU and 500 ng/kg in the USA). It was demonstrated that if AFB1 must be converted into its reactive epoxide to exert its effects, and the protein binding may play an important role in its cytotoxicity. Conversely, the AFM1 epoxidation in human liver microsomes is very limited and studies with human cell line (MCL5), expressing or not expressing cytochrome P450 enzymes, demonstrated a direct toxic potential of AFM1 in absence of metabolic activation. For this reason, while AFM1 is generally considered a detoxification product of AFB1 relatively to carcinogenicity and mutagenicity property, this is not always true for cytotoxicity activity. Aim of this work is to evaluate the intestinal absorption of AFM1 using a human in vitro model, the Caco-2 cell line. Either the parental Caco-2 cell line or its derived clone TC7, with higher metabolic competence, have been used. They were treated with different concentrations of AFM1, that mirror the milk contamination level (0.3-32 nM corresponding to 10-10,000 ng/kg), either in undifferentiated or in differentiated phase of growth. After 48 h of treatment in serum free medium, a dose dependent absorption of AFM1 has been detected in both cell lines, especially in differentiated cells, while, no appreciable effects on cell viability were observed, except for a general cellular suffering, revealed by LDH release, particularly evident in the undifferentiated cells. As well, no metabolites or AFM1 conjugates have been detected. The present results may be crucial for the evaluation of human risk to AFM1 exposure, in particular for children's population, due to their large use of milk and derivatives.
Insights
Aflatoxin M1 (AFM1) is absorbed by intestinal cells, especially in its differentiated state. This study on Caco-2 cells indicates potential risks from milk contamination, particularly for children.
Area of Science:
- Food Science
- Toxicology
- Cell Biology
Background:
- Aflatoxin M1 (AFM1) is a metabolite of Aflatoxin B1 (AFB1) found in milk.
- AFM1 is a probable human carcinogen (IARC group 2B) with regulated limits in food.
- Unlike AFB1, AFM1 exhibits direct cytotoxicity without metabolic activation.
Purpose of the Study:
- To investigate the intestinal absorption of AFM1 using an in vitro human model.
- To assess the impact of AFM1 on Caco-2 cell viability and metabolic activity.
- To evaluate potential risks associated with AFM1 exposure through dietary intake, especially in vulnerable populations.
Main Methods:
- Utilized Caco-2 and TC7 cell lines, representing human intestinal epithelium.
- Treated cells with AFM1 concentrations mirroring milk contamination levels (0.3-32 nM).
- Assessed AFM1 absorption, cell viability (LDH release), and metabolite formation over 48 hours.
Main Results:
- Demonstrated dose-dependent intestinal absorption of AFM1 in both cell lines.
- Observed higher AFM1 absorption in differentiated Caco-2 cells compared to undifferentiated cells.
- Detected cellular distress (LDH release) primarily in undifferentiated cells, with no AFM1 metabolites or conjugates found.
Conclusions:
- AFM1 is absorbed by the human intestinal barrier, with higher efficiency in differentiated cells.
- The direct toxicity of AFM1, even without metabolic activation, warrants consideration for risk assessment.
- Findings are critical for evaluating human health risks from AFM1 in milk, especially for children.
More Related Videos
09:21Inhibition of Aspergillus flavus Growth and Aflatoxin Production in Transgenic Maize Expressing the α-amylase Inhibitor from Lablab purpureus L.
Published on: February 15, 2019
08:59An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020